PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy

Several clinical studies demonstrate that there exist other immune checkpoints overexpressed in some PD-1 inhibitor-resistant tumor patients. Among them, Lymphocyte-activation gene 3 (LAG-3) is one of the important immune checkpoint molecules and has been clinically demonstrated to have synergistic...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Ning, Zhou, Yangyihua, Liu, Yujun, Zhang, Ran, Jiang, Xingjun, Ren, Caiping, Gao, Xiang, Luo, Longlong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742559/
https://www.ncbi.nlm.nih.gov/pubmed/36518768
http://dx.doi.org/10.3389/fimmu.2022.1047610

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742559/
https://www.ncbi.nlm.nih.gov/pubmed/36518768
http://dx.doi.org/10.3389/fimmu.2022.1047610

Ejemplares similares